User:Coloradochromatography/sandbox
Appearance
H2-CBD
| |||
Names | |||
---|---|---|---|
IUPAC name
2'-isopropyl-5'-methyl-4-pentyl-1',2',3',4'-tetrahydro-[1,1'-biphenyl]-2,6-diol or 2-(5-methyl-2-(prop-1-en-2-yl)cyclohexyl)-5-pentylbenzene-1,3-diol
| |||
Other names
Hydrogenated CBD, HCBD, HHCBD
| |||
Identifiers | |||
PubChem CID
|
|||
Properties | |||
C21H32O2 | |||
Molar mass | 316.5 | ||
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
H2CBD, or hydrogenated CBD, was first accessed by the Todd group in 1940 by catalytic hydrogenation of cannabidiol [1]. Gallily et al accessed the dihydro-cannabidiol H2CBD in 2006 following testing demonstrating binding affinity to CB1 receptor and their anti-inflammatory capacity [2][3]. Scialdone treated U87 cells with hydrogenated CBD in mouse models and saw a reduction in tumor weight over a 48-h period[4].
References
[edit]- ^ Jacob, A.; Todd, A. R. (1940). "119. Cannabis indica. Part II. Isolation of cannabidiol from Egyptian hashish. Observations on the structure of cannabinol". J. Chem. Soc. 119: 649-653. doi:10.1039/jr9400000649.
- ^ Ben-Shabat, S.; Hanus, L. O.; Katzavian, G.; Gallily, R. (2006). "New Cannabidiol Derivatives: Synthesis, Binding to Cannabinoid Receptor, and Evaluation of Their Antiinflammatory Activity". J. Med. Chem. 49: 1113-1117. doi:10.1021/jm050709m.
- ^ Morales, P.; Reggio, P. H.; Jagerovic, N. (2017). "An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol". Front. Pharmacol. 8: 422. doi:10.3389/fphar.2017.00422.
{{cite journal}}
: CS1 maint: unflagged free DOI (link) - ^ Scialdone, M (2016). "Hydrogenation of Cannabis Oil".
{{cite journal}}
: Cite journal requires|journal=
(help)